A systemic type of juvenile idiopathic (rheumatoid) arthritis in children and adolescents: new in the treatment (review of literature and own observations)

L.F. Bogmat, N.S. Shevchenko


The main views on one of the most complex pathological conditions in pediatric rheumatology, namely systemic arthritis, are presented. The characteristics of the classification positions of this disease are given, the pathogenetic bases, topical at the present time, the main approaches to its therapy are covered. Data from recent studies suggest that systemic arthritis belongs to a separate nosological form in the structure of juvenile idiopathic arthritis, with the development of activation of innate immunity, the presence of genetic determination and the occurrence of a cytokine imbalance with the prevalence of interleukins 1 and 6. Management of systemic arthritis requires aggressive and sufficiently rapid therapy with application of high-dose glucocorticoids and biological therapy. This disease is characterized by the development of a wide range of complications, among which a life-threatening condition — the macrophage activation syndrome deserves special attention. Early effective treatment is highly desirable, since there is a window of opportunity to stop the pathological reaction of the immune system and to prevent the further development of the disease. The overall strategy for the treatment of systemic arthritis is more important than individual therapeutic agents. The structure of systemic arthritis therapy may be wider than it is described in current recommendations and protocols.


juvenile idiopathic arthritis; systemic arthritis; treatment; review


Petty RE, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: 2nd revision. Edmonton, 2001. J Rheumatol. 2004;31:390-2. PMID: 14760812.

Still G. On a form of chronic joint disease in children. Medico-Chirurgical Transactions, London. 1897;80:47-59.

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007 Mar3;369(9563):767-78. doi: 10.1016/S0140-6736(07)60363-8.

Minden K, Niewerth M. Juvenile idiopathic arthritis-clinical subgroups and classification. 2008;67(2):102-6, 108-10. (In German). doi: 10.1007/s00393-007-0246-5.

Colebatch-Bourn AN, et al. EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Ann Rheum Dis. 2015;74(11):46-57. doi: 10.1136/annrheumdis-2015-207892.

Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives / A. Martini. Ann Rheum Dis. 2010;69(7):60-3. doi: 10.1136/ard.2010.133033.

Consolaro A, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23. doi: 10.1186/s12969-016-0085-5.

Ruperto N, Martini A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs. 2011 Sep;16(3):493-505. doi: 10.1517/14728214.2011.581662.

Giancane G, et al. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther. 2016 Dec;3(2):187-207. doi: 10.1007%2Fs40744-016-0040-4.

Vogl T, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 2007 Sep;13(9):42-9. doi: 10.1038/nm1638.

Austermann J, et al. Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions. Cell Rep. 2014 Dec;6:2112-23. doi: 10.1016/j.celrep.2014.11.020.

Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416-26. doi: 10.1038/nrrheum.2011.68.

Put K, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford). 2015;8:1507-17. doi: 10.1093/rheumatology/keu524.

Put K, et al. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis. PLoS One. 2016;2. doi: 10.1371/journal.pone.0150075.

Macaubas C, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol. 2012;142(3):362-72. doi: 10.1016/j.clim.2011.12.008.

Matzaraki V, et al. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. 2017;1:76. doi: 10.1186/s13059-017-1207-1.

Avau A, et al. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis. Cytokine Growth Factor Rev. 2015;26(1):35-45. doi: 10.1016/j.cytogfr.2014.05.005.

Gerss J, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012 Dec;71(12):91-7. doi: 10.1136/annrheumdis-2012-201329.

Woerner A, et al. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol. 2015;11(5):575-88. doi: 10.1586/1744666X.2015.1032257.

Ravelli A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;68(3):481-9. doi: 10.1136/annrheumdis-2015-208982.

Alexeeva E. Juvenile idiopathic arthritis is a diagnosis of exclusion. Pediatric Rheumatology. 2014;12:224. doi:10.1186/1546-0096-12-S1-P224.

Ringold S, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499-512. doi: 10.1002/art.38092.

Otten MH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;7:1379-86. doi: 10.1136/annrheumdis-2013-204641.

Colebatch-Bourn AN, et al. EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Ann Rheum Dis. 2015;74(11):1946-57. doi: 10.1136/annrheumdis-2015-207892.

Baranov AA, Alekseeva EI. Revmaticheskie bolezni u detej. Klinicheskie rekomendacii dlja pediatrov [Rhematic diseases in childhood. Clinical guidelines for pediatricians]. Moscow;2016. 144 p. (In Russian).

Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017 May 22. doi: 10.1097/BOR.0000000000000417.

Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(11):639-52. doi: 10.1038/nrrheum.2011.145.

Otten MH, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013;72(11):1806-12. doi: 10.1136/annrheumdis-2012-201991.

Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4):493-500. doi: 10.1080/14740338.2017.1303479.

Copyright (c) 2017 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта